Home >> Signaling Pathways >> Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Products for  Immunology/Inflammation

  1. Cat.No. 产品名称 Information
  2. GC74227 DOTA.SA.FAPi TFA DOTA.SA.FAPi TFA是一种双功能DATA5m和DOTA螯合剂,由方酸和UAMC1110组成。
  3. GC74187 Salicylic acid-13C6

    2-Hydroxybenzoic acid-13C6

    Salicylic acid-13C6是13c标记的水杨酸。
  4. GC74164 25-Hydroxytachysterol3 25-Hydroxytachysterol3是维生素D3的代谢物
  5. GC74159 MK-0731 MK-0731是一种选择性、非竞争性和变构驱动蛋白纺锤体蛋白(KSP)抑制剂,IC50为2.2 nM,pKa为7.6。
  6. GC74157 EN450 EN450是一种针对NF-κB的半胱氨酸反应性共价分子胶降解剂。
  7. GC74102 Apomine

    SR-45023A; SR 9223i; SK&F-99085

    Apomine (SR-45023A)是一种抑制胆固醇合成中甲羟戊酸/类异戊二烯途径的抗肿瘤药物。
  8. GC74090 Dimethyl fumarate-d2

    富马酸二甲酯-d2

    Dimethyl fumarate-d2是氘标记的富马酸二甲酯。
  9. GC74077 HEI3090 HEI3090是P2X7R激活剂。
  10. GC74075 SC428 SC428是一种靶向N-末端结构域的雄激素受体(AR)抑制剂。
  11. GC74073 FT-FAPI-12_9 TFA FT-FAPI-12_9 TFA是一种FAP配体,可用于合成靶向FAP的放射性示踪剂FAPI-46。
  12. GC74072 FT-FAPI-12_9 FT-FAPI-12_9其可用于合成FAP靶向放射性示踪剂FAPI-46。
  13. GC74070 INF 195 INF 195是一种NLRP3抑制剂。
  14. GC74050 PROTAC CDK4/6 degrader 1 PROTAC CDK4/6 degrader 1(化合物7f)是CDK4和CDK6的双重降解剂,DC50分别为10.5和2.5 nM。
  15. GC74047 UR778Br UR778Br靶向IQGAP1蛋白的GTP酶激活蛋白相关结构域(GRD结构域)。
  16. GC74045 Zoracopan Zoracopan是一种选择性补体因子D(CFD)抑制剂。
  17. GC74042 SpiD3 SpiD3是一种新型的螺环二聚体。
  18. GC74032 Enpp-1-IN-20 Enpp-1-IN-20(化合物31)是一种外核苷酸焦磷酸酶/磷酸二酯酶1 (ENPP1)抑制剂,IC50为0.09 nM。
  19. GC74030 ASCT2-IN-2 ASCT2-IN-2(化合物25e)是一种ASCT2抑制剂,IC50为5.14μM。
  20. GC74029 ASCT2-IN-1 ASCT2-IN-1(化合物20k)是一种ASCT2抑制剂,在A549和HEK293细胞中的IC50值分别为5.6 μM和3.5 μM。
  21. GC74024 BPU BPU在亚g1期阻止细胞周期进程。
  22. GC74013 FOSL1 degrader 1 FOSL1 degrader 1(4)是一种T-5224-PROTAC,能有效降解FOSL1 (AP-1),抑制HNSCC中癌干性基因的表达。
  23. GC74007 SelSA SelSA是一种选择性的口服活性组蛋白去乙酰化酶6 (HDAC6)抑制剂,IC50为56.9 nM。
  24. GC74005 AK59 AK59是一种STING降解剂,通过利用HERC4(一种hect结构域E3连接酶)起作用。
  25. GC74001 TS-24 TS-24是组织蛋白酶S的抑制剂,IC50为4.3μM。
  26. GC73996 PROTAC AR/AR-V7 degrader-1 PROTAC AR/AR-V7 degrader-1(27c)是一种基于PROTAC的双AR AR-V7降解器,AR和AR-V7的DC50值分别为2.67和2.64μM。
  27. GC73995 XL44 XL44是一种hRpn13结合物,可诱导hRpn13依赖性细胞凋亡,并通过pclaf依赖性机制限制细胞活力。
  28. GC73994 UM4118 UM4118是一种铜离子载体,可以引发基于线粒体的非正规形式的细胞死亡,称为铜中毒。
  29. GC73990 SDU-071 SDU-071是BRD4-p53抑制剂的强效口服活性抑制剂。
  30. GC73982 NSD-IN-3 NSD-IN-3(化合物3)是一种强效的核受体结合SET结构域(NSD)抑制剂。
  31. GC73980 GGTI-2417 GGTI-2417是GGTase I的强效选择性抑制剂。
  32. GC73973 MY-1442 MY-1442(I-3)是微管蛋白聚合抑制剂。
  33. GC73950 SC912 SC912是AR-V7抑制剂(IC50 = 0.36 μM)。
  34. GC73943 Polθ/PARP-IN-1 Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。
  35. GC73942 NT-0249 free base NT-0249 free base是一种口服活性NLRP3抑制剂。
  36. GC73940 BFC1108 BFC1108是一种小分子Bcl-2功能转换器。
  37. GC73939 ATPase-IN-3 ATPase-IN-3(化合物6)是一种atp酶抑制剂。
  38. GC73932 WK369 WK369是一种新型的BCL6小分子抑制剂,具有良好的抗卵巢癌生物活性,可诱导细胞周期阻滞和细胞凋亡。
  39. GC73928 BDM19 BDM19并单独或与BCL-2/BCL-XL抑制剂Navitoclax联合诱导细胞凋亡。
  40. GC73925 YSR734 YSR734(化合物21)是一种共价HDAC抑制剂,对HDAC1、HDAC2和HDAC3的IC50值分别为110 nM、154 nM和143 nM。
  41. GC73915 PSMA-Val-Cit-PAB-Azide PSMA-Val-Cit-PAB-Azide是ADC的药物接头偶联物。
  42. GC73900 HA-9104 HA-9104是一种有效的选择性抑制剂,通过几乎靶向UBE2F的V30口袋来抑制cullin-5 nedylation。
  43. GC73894 BNT411 BNT411是一种选择性TLR7激动剂,可以诱导体内和体外IFNa的释放。
  44. GC73893 BLU-222 BLU-222是一种口服活性高选择性CDK2抑制剂。
  45. GC73881 PRO-6E PRO-6E是一种基于小脑配体的口服活性PROTAC,在MKN-45细胞中,在1 μM时可诱导MET降解,最大降解率为81.9%。
  46. GC73868 WD6305 TFA WD6305 TFA是一种有效的mettl3靶向PROTAC降解剂。
  47. GC73867 TNFα activity modulator 3 TNFα activity modulator 3(例6)是TNF活性调节剂,可抑制TNFα诱导的NF-κB活化,可用于相关研究。
  48. GC73865 SNX281 SNX281是一种系统活性STING激动剂,与STING蛋白结合,促进cGAS STING通路的信号转导,并增加细胞对肿瘤细胞的反应。
  49. GC73822 GNE-900 GNE-900是一种ATP竞争性、选择性和口服活性的ChK1抑制剂,ChKl和ChK2的IC50分别为0.0011和1.5µM。
  50. GC73818 TLR7 agonist 20 hydrochloride TLR7 agonist 20 hydrochloride是咪唑并喹啉类似物。
  51. GC73813 IOX5 IOX5是一种选择性脯氨酸羟化酶(PHD)抑制剂。

Items 101 to 150 of 4267 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction